News Quantified

BYSI – beyondspring, inc. - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC [Seeking Alpha]

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 [Yahoo! Finance]

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

Form SC 13G/A BeyondSpring Inc. Filed by: Decheng Capital Management III (Cayman), LLC

Form 6-K BeyondSpring Inc. For: Jun 30

Top News Gainers

3/19 Beyondspring Inc (NASDAQ: BYSI) had its "buy" rating re-affirmed by analysts at William Blair. 22.2%

9/6 BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference 19.2%

4/28 Beyondspring Inc (NASDAQ: BYSI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.8%

1/10 Beyondspring Inc (NASDAQ: BYSI) is now covered by analysts at Nomura. They set a "buy" rating and a $34.00 price target on the stock. 11.3%

12/9 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting 4.4%

9/10 BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer 4.3%

5/16 BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting 4.2%

12/19 BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies 3.4%

10/23 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. 3.1%

9/11 BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019 2.7%

Top News Decliners

10/24 BeyondSpring Announces Proposed Public Offering of Ordinary Shares -26.8%

2/10 BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients -19.4%

7/16 BeyondSpring Announces Proposed Public Offering of Ordinary Shares -10.4%

3/11 Form 6-K BeyondSpring Inc. For: Mar 11 -8.7%

4/30 Form 20-F BeyondSpring Inc. For: Dec 31 -8.6%

3/11 BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 -8.1%

5/21 Form 424B5 BeyondSpring Inc. -6.8%

4/20 Beyondspring Inc (NASDAQ: BYSI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -6.1%

10/23 BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia -5.2%

8/23 BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia -5.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day